Novo Nordisk, a top antidiabetics producer incorporated in Denmark, recently raised the curtain on construction of the world's biggest insulin preparation and filling factory in TEDA. With a total investment of 381 million USD and covering around 88,711 square meters, the new plant will become Novo Nordisk's most important insulin production base in the Asia-Pacific region. After starting operation in 2012, it is designed to provide the insulin injection equipment for customers in Mainland China and even the whole world. In particular, this Tianjin-based factory will offer nearly 500 new jobs.